GPIbIXVreceptorer

GPIbIXVreceptorer, also known as GPIb-IX-V, are a hetero‑multimeric complex of glycoproteins located on the surface of human platelets. The complex is composed of four distinct subunits: GPIbα, GPIbβ, GPIIX, and GPV. GPIbα forms the ligand‑binding site that recognizes von Willebrand factor (VWF) and therefore mediates platelet adhesion to subendothelial collagen during vascular injury. GPIbβ associates with the extracellular domain of GPIbα and contributes to ligand binding and complex stability. GPIIX and GPV have relatively short extracellular portions and provide linkage to the platelet cytoskeleton, while the intracellular tail of GPIbα contains signaling motifs that activate downstream pathways involving MAPK and PI3K, leading to platelet activation and aggregation.

The GPIbIXV complex functions primarily as a high‑affinity receptor for VWF at low shear rates, facilitating the formation of the primary hemostatic plug. It is also implicated in platelet tethering under arterial flow. Genetic mutations that affect any of the subunits can lead to Bernard‑Soulier syndrome, a rare inherited platelet disorder characterized by macrothrombocytopenia, prolonged bleeding, and deficient VWF binding. Autosomal recessive loss‑of‑function alleles of the GP1BA, GP1BB, or GP1BBZ genes correspond to disruptions of the GPIbα, GPIbβ, or GPIIX subunits, respectively.

Therapeutic interventions targeting the GPIbIXV complex are used in the management of certain thrombotic disorders. For example, the monoclonal antibody eptifibatide competes with VWF for GPIbα binding and reduces platelet adhesion in acute coronary syndromes. Additionally, receptor‑blocking agents such as Reopro (abciximab) are employed to prevent platelet aggregation during percutaneous coronary interventions. Recent research explores small‑molecule inhibitors and peptide mimetics that modulate GPIbIXV activity while minimizing bleeding risk.

Overall, GPIbIXVreceptorer are essential for primary hemostasis and represent a clinically relevant target for antithrombotic therapy.